In this era of emerging disease modifying treatments, alongside increased media coverage of “imminent” breakthroughs in blood-based biomarkers what does this mean for the provision of care for the millions of people living with dementia globally? Is there a risk that these novel treatments, could divert attention and resources away from the development and rollout of robust care plans?
In this fireside chat hosted by ADI Board Chair, Dale Goldhawk, joined by Prof Sube Banerjee, Pro-Vice Chancellor & Professor of Dementia (University of Nottingham, UK) and Dame Louise Robinson, Professor of Primary Care and Ageing (Newcastle University, UK) we will be exploring these very questions, aiming to dissect critical issues surrounding dementia care, treatment, and policy, offering insights from leading experts in the field. Join us for an enlightening discussion on navigating the complexities of dementia care in the face of evolving treatment paradigms.
Do you have a highlight from this fireside chat? Let us know by tagging us on our social channels @AlzDisInt
Find more information on our website https://www.alzint.org/
Sign up to our email list https://www.alzint.org/newsletter
Dr Clarissa Giebel
How do you feel about the promose of new treatments?